Journal article
Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi
- Abstract:
-
Background
Antimicrobial therapy is essential for the treatment of enteric fever, the infection caused by Salmonella serovars Typhi and Paratyphi A. However, an increase in resistance to key antimicrobials and the emergence of MDR and XDR in Salmonella Typhi poses a major threat for efficacious outpatient treatments.
Objectives We recently identified tebipenem, an oral carbapenem licensed for use for respiratory tract infections in Japan, as a potential alternative treatment for MDR/XDR Shigella spp. Here, we aimed to test the in vitro antibacterial efficacy of this drug against MDR and XDR typhoidal Salmonella.
Methods We determined the in vitro activity of tebipenem in time–kill assays against a collection of non-XDR and XDR Salmonella Typhi and Salmonella Paratyphi A (non-XDR) isolated in Nepal and Bangladesh. We also tested the efficacy of tebipenem in combination with other antimicrobials.
Results We found that both XDR and non-XDR Salmonella Typhi and Salmonella Paratyphi A are susceptible to tebipenem, exhibiting low MICs, and were killed within 8–24 h at 2–4×MIC. Additionally, tebipenem demonstrated synergy with two other antimicrobials and could efficiently induce bacterial killing.
Conclusions Salmonella Paratyphi A and XDR Salmonella Typhi display in vitro susceptibility to the oral carbapenem tebipenem, while synergistic activity with other antimicrobials may limit the emergence of resistance. The broad-spectrum activity of this drug against MDR/XDR organisms renders tebipenem a good candidate for clinical trials.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 207.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/jac/dkab326
Authors
- Publisher:
- British Society for Antimicrobial Chemotherapy
- Journal:
- Journal of Antimicrobial Chemotherapy More from this journal
- Volume:
- 76
- Issue:
- 12
- Pages:
- 3197-3200
- Publication date:
- 2021-09-17
- Acceptance date:
- 2021-08-05
- DOI:
- EISSN:
-
1460-2091
- ISSN:
-
0305-7453
- Pmid:
-
34534310
- Language:
-
English
- Keywords:
- Pubs id:
-
1195354
- Local pid:
-
pubs:1195354
- Deposit date:
-
2021-12-21
- ARK identifier:
Terms of use
- Copyright holder:
- Mylona et al.
- Copyright date:
- 2021
- Rights statement:
- © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record